SZSE:300347 (China)
Business Description
Hangzhou Tigermed Consulting Co Ltd
NAICS : 541711
SIC : 8731
Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053
Compare
Compare
Traded in other countries / regions
300347.China
•
5HZ1.Germany
•
03347.Hong Kong
•
HNGZY.USA
Description
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.52 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | 0.45 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 15.61 | |||||
| Beneish M-Score | -1.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 24.9 | |||||
| 3-Year EBITDA Growth Rate | 69.9 | |||||
| 3-Year EPS without NRI Growth Rate | 73.7 | |||||
| 3-Year FCF Growth Rate | 28.3 | |||||
| 3-Year Book Growth Rate | 76.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 25.25 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.97 | |||||
| 9-Day RSI | 41.24 | |||||
| 14-Day RSI | 44.25 | |||||
| 6-1 Month Momentum % | 20.92 | |||||
| 12-1 Month Momentum % | -27.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.52 | |||||
| Quick Ratio | 3.51 | |||||
| Cash Ratio | 2.69 | |||||
| Days Inventory | 0.62 | |||||
| Days Sales Outstanding | 39.71 | |||||
| Days Payable | 13.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.48 | |||||
| Dividend Payout Ratio | 0.09 | |||||
| 3-Year Dividend Growth Rate | 31 | |||||
| Forward Dividend Yield % | 0.48 | |||||
| 5-Year Yield-on-Cost % | 2.81 | |||||
| 3-Year Average Share Buyback Ratio | -5.2 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 41.66 | |||||
| Operating Margin % | 26.17 | |||||
| Net Margin % | 47.92 | |||||
| ROE % | 16.85 | |||||
| ROA % | 13.11 | |||||
| ROIC % | 11.18 | |||||
| ROC (Joel Greenblatt) % | 231.84 | |||||
| ROCE % | 19.27 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 30.34 | |||||
| Forward PE Ratio | 37.63 | |||||
| PE Ratio without NRI | 30.59 | |||||
| Shiller PE Ratio | 107.55 | |||||
| Price-to-Owner-Earnings | 31.93 | |||||
| PEG Ratio | 0.46 | |||||
| PS Ratio | 14.52 | |||||
| PB Ratio | 4.86 | |||||
| Price-to-Tangible-Book | 5.67 | |||||
| Price-to-Free-Cash-Flow | 74.85 | |||||
| Price-to-Operating-Cash-Flow | 59.8 | |||||
| EV-to-EBIT | 20.41 | |||||
| EV-to-EBITDA | 20.41 | |||||
| EV-to-Revenue | 13.1 | |||||
| EV-to-Forward-Revenue | 11.28 | |||||
| EV-to-FCF | 67.53 | |||||
| Price-to-Projected-FCF | 3.92 | |||||
| Price-to-DCF (Earnings Based) | 0.81 | |||||
| Price-to-DCF (FCF Based) | 5.58 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.23 | |||||
| Price-to-Graham-Number | 2.78 | |||||
| Price-to-Net-Current-Asset-Value | 22.03 | |||||
| Price-to-Net-Cash | 55.67 | |||||
| Earnings Yield (Greenblatt) % | 4.9 | |||||
| Forward Rate of Return (Yacktman) % | 20.76 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 6,129.449 | ||
| EPS (TTM) (¥) | 3.38 | ||
| Beta | 1.4 | ||
| Volatility % | 60.89 | ||
| 14-Day RSI | 44.25 | ||
| 14-Day ATR (¥) | 5.253035 | ||
| 20-Day SMA (¥) | 108.382 | ||
| 12-1 Month Momentum % | -27.73 | ||
| 52-Week Range (¥) | 77.36 - 180 | ||
| Shares Outstanding (Mil) | 872.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hangzhou Tigermed Consulting Co Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||